BioNTech Records Stupendous Q2 Sales, Earnings Growth; Estimates FY21 COVID-19 Vaccine Revenues Of €15B

BioNTech SE BNTX reports Q2 FY21 revenues of €5.31 billion compared to €41.7 million a year ago, primarily due to an increase in the supply of COVID-19 vaccine worldwide. Revenues more than doubled from €2.04 billion sales in Q1 FY21.
As of July 21, BioNTech and its partner Pfizer Inc PFE have shipped approximately one billion doses of its COVID-19 vaccine (BNT162b2).
The companies have signed orders of more than 2.2 billion doses for delivery in 2021 and more than one billion doses for 2022 and beyond.
BioNTech generated an operating income of €4.19 billion, a turnaround from a loss of €80.9 million a year ago.
Net profit also saw a massive growth at €2.7 billion versus a loss of €88.3 million in Q2 2020. Cash and cash equivalents stood at €914.1 million.
Outlook: BioNTech estimates that COVID-19 vaccine revenues upon delivery of currently signed supply contracts are expected to reach around €15.5 billion (compared to €12.4 billion previously).
It targets a full-year 2021 manufacturing capacity of 3 billion doses and up to 4 billion doses for 2022.
Price Action: BNTX shares are trading 5.14% higher at $409 during the premarket session on the last check Monday.
Image by x3 from Pixabay